Metastatic Breast Cancer Education
Metastatic breast cancer spans multiple molecular subtypes, each with distinct treatment algorithms and emerging therapies. Knowledge Med sessions use interactive case simulations to help community providers navigate subtype-specific treatment decisions, CDK4/6 inhibitor sequencing, and integration of novel agents.
Non-promotional, independently reviewed sessions led by faculty from Johns Hopkins, Columbia, Mount Sinai, and other leading academic medical centers.
What Providers Navigate
Physicians managing metastatic breast cancer face evolving treatment decisions that interactive, independently reviewed education can help address.
- Navigating CDK4/6 inhibitor selection and sequencing after progression
- Identifying and managing endocrine resistance mechanisms
- Integrating genomic profiling (ESR1, PIK3CA) into treatment decisions
- Balancing efficacy with quality of life in later lines of therapy
What Sessions Cover
Knowledge Med mBC sessions use interactive case simulations to address these topics and more.
- First-line endocrine-based therapy selection in HR+/HER2- mBC
- Sequencing strategies after CDK4/6 inhibitor progression
- Role of PI3K/AKT/mTOR pathway inhibitors
- Integrating antibody-drug conjugates in later-line treatment
Interactive mBC Sessions
Case Simulations
Work through realistic metastatic breast cancer patient cases with expert faculty, making treatment decisions at each stage.
Live Polling
See how your clinical decisions compare to peers in real time — revealing practice patterns and knowledge gaps.
Personalized Report
Receive a session summary with your individual responses, peer benchmarks, and key mBC clinical takeaways.
More Solid Tumor Sessions
Knowledge Med offers interactive sessions across many indications — these are just some of the areas we cover.
Metastatic Colorectal Cancer
mCRC — Biomarker-driven first-line therapy selection in mCRC
HER2-Positive Breast Cancer
HER2+ — First-line treatment selection in HER2+ metastatic breast cancer
Triple-Negative Breast Cancer
TNBC — Immunotherapy in first-line metastatic TNBC: patient selection and regimens
Non-Small Cell Lung Cancer
NSCLC — Biomarker-driven first-line therapy selection in advanced NSCLC
Join a mBC Session
Third-party, non-promotional metastatic breast cancer education led by faculty from leading academic medical centers. Case simulations. Live polling. Personalized insights.
Join a Session